Core Viewpoint - Lantheus Holdings, Inc. is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934, with claims centered around misleading information regarding the company's revenue outlook and market dynamics for its key product, Pylarify [1][4]. Company Overview - Lantheus develops, manufactures, and commercializes diagnostic and therapeutic products, particularly focusing on oncology, with Pylarify being a significant product used for prostate cancer diagnosis and treatment [3]. Allegations of the Lawsuit - The lawsuit claims that Lantheus executives misrepresented the company's revenue projections and downplayed risks related to competition, pricing, and macroeconomic factors [4]. - It is alleged that Lantheus's optimistic sales growth reports for Pylarify did not align with actual market conditions, leading to significant stock price declines following disappointing earnings reports [4][5]. Financial Impact - On May 7, 2025, Lantheus reported a year-over-year decrease in Pylarify sales, leading to a reduction in full-year growth projections from low-single-digit to flat-to-low single-digit percent growth, resulting in a stock price drop of over 23% [5]. - Following another disappointing announcement on August 6, 2025, which revealed an 8.3% year-over-year decline in Pylarify sales, the stock price fell nearly 29% [6]. Legal Process - Investors who purchased Lantheus securities during the specified class period (February 26, 2025, to August 5, 2025) have until November 10, 2025, to seek appointment as lead plaintiff in the class action lawsuit [1][7].

Core Viewpoint - A securities class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly providing misleading information to investors regarding the competitive position of its product Pylarify during the class period from February 26, 2025, to August 5, 2025 [1][2]. Group 1 - The lawsuit claims that Lantheus made overwhelmingly positive statements while concealing material adverse facts about Pylarify's competitive dynamics [2]. - It is alleged that the company was not adequately equipped to assess pricing and competition for Pylarify, which led to a risk of price erosion and affected revenue and growth potential [2]. - The complaint states that these misleading statements resulted in shareholders purchasing Lantheus securities at artificially inflated prices [2]. Group 2 - Investors who acquired shares of Lantheus are encouraged to contact the law firm before the lead plaintiff motion deadline on November 10, 2025 [3]. - The lead plaintiff will represent other class members in directing the litigation process [3].

Core Viewpoint - A class action lawsuit has been filed against Lantheus Holdings, Inc. for allegedly misleading investors regarding the competitive position of its key product, Pylarify, during the specified class period [1][2]. Group 1: Allegations and Misleading Statements - The lawsuit claims that Lantheus made materially false and misleading statements about Pylarify's competitive position, failing to accurately assess pricing and competitive dynamics [2]. - It is alleged that Lantheus did not properly disclose the implications of a price increase in early 2025, which created opportunities for competitive pricing and risked Pylarify's revenue and growth potential [2][3]. Group 2: Financial Impact and Stock Performance - Following disappointing results announced on August 6, 2025, Lantheus reported an 8.3% year-over-year decline in Pylarify's performance and significantly reduced its growth projections for fiscal year 2025 [4]. - The announcement led to a sharp decline in Lantheus' stock price, dropping from $72.83 per share on August 5, 2025, to $51.87 per share on August 6, 2025, representing a decline of approximately 28.8% in one day [4].

LOS ANGELES--(BUSINESS WIRE)---- $LNTH--LNTH Investors Have Opportunity to Lead Lantheus Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm. ...

ATLANTA, Sept. 10, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH). The lawsuit alleges, among other things, that Defendants created the false impression that they possessed reliable information pertaining to the Company’s projected revenue outlook and anticipated growth while also minimizing risk from competition and pricing dynamics, seasonality, and macroeconomic fluctuations. If you purchased shares o ...

Core Viewpoint - A class action lawsuit has been initiated against Lantheus Holdings, Inc. due to allegations of misleading statements regarding the competitive position of its product Pylarify, which led to inflated stock prices and subsequent losses for investors [1][3]. Company Performance - Lantheus reported disappointing first quarter results on May 7, 2025, with Pylarify's performance falling short of market expectations [4]. - On August 6, 2025, Lantheus announced further disappointing results, revealing an 8.3% year-over-year decline in Pylarify's performance and significantly reduced growth projections for fiscal year 2025 [4]. Stock Market Reaction - Following the negative announcements, Lantheus' stock price plummeted from $72.83 per share on August 5, 2025, to $51.87 per share on August 6, 2025, marking a decline of approximately 28.8% in just one day [5].

Core Viewpoint - A securities fraud lawsuit has been filed against Lantheus Holdings Inc. and its executives, alleging that they misled investors regarding the performance and pricing of its key product, Pylarify, leading to significant stock price declines [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Lantheus and its executives provided false assurances about Pylarify's market leadership and pricing strength, while concealing competitive pressures and price erosion [2]. - Following the release of disappointing quarterly results in May and August 2025, Lantheus' stock experienced declines of over 23% and 28%, respectively, due to reduced revenue guidance and increased competition [2]. Group 2: Investor Eligibility - Investors who purchased Lantheus Holdings Inc. common stock between February 26, 2025, and August 5, 2025, and have experienced losses may be eligible to participate in the lawsuit, regardless of whether they sold their shares [3]. Group 3: Next Steps for Investors - The deadline for investors to seek appointment as lead plaintiff is November 10, 2025, and a class has not yet been certified [4]. - Investors are encouraged to contact Block & Leviton for more information on how to proceed if they have incurred losses [4]. Group 4: Whistleblower Information - Individuals with non-public information about Lantheus Holdings Inc. are encouraged to assist in the investigation or report to the SEC under the whistleblower program, potentially receiving rewards of up to 30% of any successful recovery [5]. Group 5: Firm Background - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [6].

Question-and-Answer SessionSo for those in the audience who aren't familiar with the Lantheus story, can you mind just giving me a quick background on the company?Brian MarkisonCEO & Director Yes. So a quick background. Also, please note our safe harbor and forward-looking statements, please. Background on the company, founded coming out of the Manhattan project, had a number of different names over time, but always been in the nuclear medicine business, always leadership going back in time with products li ...

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Lantheus Holdings, Inc. ("Lantheus†or the "Company†) (NASDAQ:LNTH) investors concerning the Company's possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On August 6, 2025, Lantheus announced disappointing second quarter 2025 results, revealing earnings-per-share ("EPS†) and revenue figures that m. ...

Question-and-Answer SessionSo for those in the audience who aren't familiar with the Lantheus story, can you mind just giving me a quick background on the company?Brian MarkisonCEO & Director Yes. So a quick background. Also, please note our safe harbor and forward-looking statements, please. Background on the company, founded coming out of the Manhattan project, had a number of different names over time, but always been in the nuclear medicine business, always leadership going back in time with products li ...